Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
Date:2/19/2009

mong other purchase accounting related items, a charge of $1.27 billion to write off in-process research and development related to the acquisition of the former Merck Generics business. Excluding purchase accounting items from both periods, as well as the non-cash impairment charges from the current quarter, earnings from operations would have been $180.2 million in the current quarter compared to $118.5 million in the prior year.

The increase in operating income in the current quarter is due to increased sales and gross profit, as well as slightly lower R&D and SG&A expense, both of which decreased by 4%. SG&A expense was higher in the prior year mainly due to higher professional and consulting fees and other costs associated with the integration of the former Merck Generics business. Additionally, the current quarter included net charges of $16.5 million related to the settlement of certain litigation.

Interest expense for the current quarter totaled $92.3 million compared to $133.4 million for the three months ended Dec. 31, 2007. During the three months ended Dec. 31, 2007, the company repaid high interest-bearing bridge financing with the proceeds from the issuances of common stock and preferred stock, and refinanced its debt, reducing the interest rate in effect on several outstanding borrowings. Additionally, debt repayments made during calendar year 2008, as well as favorable hedging strategies, including variable to fixed interest rate swaps, and lower interest rates resulted in the reduction in interest expense.

Other expense, net was $9.2 million for the three months ended Dec. 31, 2008, compared to $43.9 million in the same prior year period. The most significant item in the prior year was $57.2 million related to the early repayment of certain debt and expensing certain financing fees.

For the calendar year ended Dec. 31, 2008, total revenues were $5.14 billi
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Safety, Proof of Mechanism of a Potential Oral Antagonist ... 20 Amira Pharmaceuticals, Inc., announced today the initiation ... internally discovered oral drug candidate for the treatment and ... arachidonic acid pathway.AM211 is an oral, selective antagonist of ...
... (Nasdaq: BNVI ) today announced the poster presentation ... compound and mechanism of action for its preclinical cancer drug ... conference of the American Association of Cancer Research (AACR) in ... , BN108, ...
... Group of AdvisorsSAN DIEGO, April 20 Trius Therapeutics, ... Board, naming Donald H. Batts, MD, FACP, FIDSA, and ... members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of Infectious ...
Cached Biology Technology:Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2
(Date:7/11/2014)... and Mineral Research awarded Michael F. Holick, PhD, MD, ... 2014 Louis V. Avioli Award. Holick, a professor of ... for revolutionizing the understanding of vitamin D and its ... a member of the American Society for Bone and ... mineral basic research. It is named for ASBMR,s first ...
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... PITTSBURGH, Jan. 3 Mice bred to age too quickly ... scientists at the University of Pittsburgh School of Medicine injected ... of young, healthy animals. Instead of becoming infirm and dying ... cells improved their health and lived two to three times ...
... line of attack against pancreatitis and pancreatic cancer is ... substantial new funding from the Medical Research Council (MRC). ... digestion turn on the pancreas itself. Chronic pancreatitis increases ... five-year survival rate of all common cancers in the ...
... kind, researchers at Queens College and Mount Sinai School ... and maternal gestational diabetes together may cause a 14-fold ... six year olds. The data are published in the ... Adolescent Medicine , one of the JAMA/Archives journals. ...
Cached Biology News:Pitt: A shot of young stem cells made rapidly aging mice live longer and healthier 2New stage in fighting pancreatic cancer 2Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2
... pump, available in a single and twin head, ... design. With the most compact, lightweight package in ... in portable air and gas applications., Available ... T2-01TH). , Delivers 1.5 and 2.0 liters per ...
... for the mechanical harvesting of cells • ... even contact with the growth surface • ... flasks • Individually wrapped • Sterilized by ... CLS number is a new product number, ...
... The Yeast ProtoArray high-density functional protein microarray ... rapid elucidation of proteinprotein interactions on a ... S. cerevisiae open reading frames (ORFs) expressed ... duplicate on a 1 inch x 3 ...
... Yeast nitrogen base (YNB) is a base medium ... media. YNB contains ammonium sulfate but does not ... pouches are available. Each pouch contains reagents ... Pichia media or 1000 ml of 10X YNB ...
Biology Products: